IFN Signaling and ICB Resistance: Time is on Tumor's Side

Alejandro López-Soto; Segundo Gonzalez; Alicia R Folgueras

doi:10.1016/j.trecan.2017.01.004

IFN Signaling and ICB Resistance: Time is on Tumor's Side

Trends Cancer. 2017 Mar;3(3):161-163. doi: 10.1016/j.trecan.2017.01.004. Epub 2017 Jan 30.

Authors

Alejandro López-Soto¹, Segundo Gonzalez², Alicia R Folgueras³

Affiliations

¹ Departamento de Biología Funcional, Inmunología, Facultad de Medicina, Instituto Universitario de Oncología (IUOPA), Universidad de Oviedo, 33006 Oviedo, Spain. Electronic address: lopezsalejandro@uniovi.es.
² Departamento de Biología Funcional, Inmunología, Facultad de Medicina, Instituto Universitario de Oncología (IUOPA), Universidad de Oviedo, 33006 Oviedo, Spain.
³ Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Instituto Universitario de Oncología (IUOPA), Universidad de Oviedo, 33006 Oviedo, Spain. Electronic address: arfolgueras@uniovi.es.

PMID: 28718428
DOI: 10.1016/j.trecan.2017.01.004

Abstract

Activation of antitumor immunity upon immune checkpoint blockade (ICB) is one of the most promising strategies in cancer therapy. However, ICB resistance is frequently observed in cancer preclinical models and patients. A recent report in Cell reveals that sustained interferon (IFN) signaling confers tumor resistance to ICB by inducing the expression of an immunosuppressive multigenic program.

Publication types

Review
Comment

MeSH terms

Drug Resistance, Neoplasm / genetics
Drug Resistance, Neoplasm / immunology*
Gene Expression Regulation, Neoplastic / immunology
Genes, cdc / drug effects
Genes, cdc / immunology*
Humans
Interferons / genetics
Interferons / immunology*
Neoplasms / genetics
Neoplasms / immunology
Neoplasms / therapy*
Signal Transduction / immunology

Substances

Interferons